Preclinical Remodeling of Human Prostate Cancer through the PTEN/AKT Pathway
Figure 1
Modeling prostate cancer in the PTEN conditional knockout mouse model. (A) PSACre/PTENloxP/loxP can be used to screen for tumor response against targeted therapies in chemoprevention, intervention, or regression models using noncastrated or castrated mice. (B) Comprehensive genomic and proteomic analyses can be performed in PSACre/PTENloxP/+, PSACre/PTENloxP/loxP, or bigenic mutants to identify candidate genes or proteins signatures aberrantly expressed between different pathologic, genomic, or temporal disease conditions. (C) Cooperation between genetic and nongenetic factors can be assessed in tumor development in both homozygous and heterozygous PTEN-conditional mutant mice.
